Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Dizon, Don S.; Krilov, Lada; Cohen, Ezra E.W.; Gangadhar, Tara C.; Ganz, Patricia A.; Hensing, Thomas A.; Hunger, Stephen P.; Krishnamurthi, Smitha; Lassman, Andrew B.; Markham, Merry Jennifer; Mayer, Erica L.; Neuss, Michael N.; Pal, Sumanta K.; Richardson, Lisa C.; Schilsky, Richard L.; Schwartz, Gary K.; Spriggs, David R.; Villalona‐Calero, Miguel A.; Villani, Gina; Masters, Gregory A.

doi:10.1200/jco.2015.65.8427

Cited by 152 publications

(94 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TTFields have been found to prolong survival in patients with glioblastoma multiforme (GBM), which led to its approval by the FDA for recurrent and newly diagnosed GBM after surgery and radiotherapy with adjuvant temozolomide (7)(8)(9)(10)(11). In addition, this treatment modality has been recognized by the American Society of Clinical Oncology (ASCO) as an advancement in cancer treatment due to its novel approach, effectiveness, and low toxicity profile (12). The most recent National Comprehensive Cancer Network (NCCN) guidelines recommended TTFields in newly diagnosed GBM as a category 2A treatment for patients with a good performance status (13).…”

Section: Introductionmentioning

confidence: 99%

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

289

181

View full text Add to dashboard Cite

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. Clin Cancer Res; 24(2); 266-75. Ó2017 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

289

181

View full text Add to dashboard Cite

show abstract

“…1) Hepatocellular carcinoma (HCC) is one of the most common types of cancer and the second leading cause of cancer-related death with the 5th highest morbidity rate according to recent studies. 2,3) Currently, there are a few treatment options of HCC, including surgical resection and liver transplantation.…”

mentioning

confidence: 99%

“…and observed obvious anti-inflammatory, analgesic and anti-tumor effects. 9,10) 1,2-Dimethoxy-N-methyl [1,3] benzodioxolo [5,6-c]-phenanthridinium, commonly known as Chelerythrine (CHE), is a kind of benzophenanthridine alkaloid and the main alkaloid constituent of Toddalia asiatica. 10,11) CHE has a wide range of biological activities including antimicrobial, antifungal, anti-inflammatory, anti-parasitic and anti-tumor effects.…”

mentioning

confidence: 99%

Chelerythrine Inhibits Human Hepatocellular Carcinoma Metastasis <i>in Vitro</i>

Zhu

Pan

Zhang

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Chelerythrine (CHE) is a type of benzophenanthridine alkaloid found in many herbs and is also the main alkaloid constituent of Toddalia asiatica (L.) LAM. It has been proven to have various activities including antitumor, antifungal, anti-inflammatory and anti-parasitic effects. We have previously demonstrated that CHE can inhibit proliferation and promote apoptosis in human hepatocellular carcinoma (HCC) cells. However, the effect of CHE on the metastasis of HCC and its related molecular mechanisms have yet to be validated. In this study, we investigated the effects of CHE on the migration and invasion of the HCC cell line Hep3B. Key words Chelerythrine; hepatocellular carcinoma; metastasis Despite the groundbreaking progress in the diagnosis and treatment of malignant tumors, cancer remains the greatest health concern in the world due to high morbidity and mortality.1) Hepatocellular carcinoma (HCC) is one of the most common types of cancer and the second leading cause of cancer-related death with the 5th highest morbidity rate according to recent studies.2,3) Currently, there are a few treatment options of HCC, including surgical resection and liver transplantation. However, most of the patients who undergo the treatments mentioned above experience new tumors in the residual liver, and their five-year survival rate is no more than 10%.4-6) Metastasis and recurrence are the two main reasons for poor prognosis in patients with HCC. 7) Therefore, key efforts should be focused on blocking invasion and migration of cancer cells.Natural products have been used to treat cancer for over 40 years. Approximately 60% of the clinically used anti-cancer drugs are natural products or derivatives.8) The traditional Chinese medicinal herb Toddalia asiatica LAM. is a kind of traditional folk medicine commonly used in southwest China. It can disperse pathogenic wind and relieve pain, remove blood stasis to stop bleeding, clear away toxic materials and alleviate edema, as stated in the Chinese theory of medicine. We extracted total alkaloids from Toddalia asiatica LAM. and observed obvious anti-inflammatory, analgesic and anti-tumor effects. 10,11) CHE has a wide range of biological activities including antimicrobial, antifungal, anti-inflammatory, anti-parasitic and anti-tumor effects. [11][12][13][14] Regarding cancer therapy, we have reported that CHE can inhibit proliferation and promote apoptosis in HepG2 cells.15) However, the effect of CHE on the metastasis of HCC and its related molecular mechanisms are still undefined.Studies have shown that tumor metastasis involves a serious of complex processes. The primary tumor cells proliferate, invade the basement membrane (BM) and enter the blood and lymphatic circulation. Finally, metastases are formed at distal sites, resulting in secondary tumors. 16,17) In the process described above, the degradation of the extracellular matrix (ECM) is key to tumor migration and invasion. Many protein kinases play important roles in the degradation of the ECM, including matrix metalloprote...

show abstract

“…Наиболее перспективным направлением является иммунотерапия -тера-пия, нацеленная на активацию естественных за-щитных механизмов организма. Иммунотерапия была признана Американским обществом кли-нической онкологии (ASCO, American Society of Clinical Oncology) главным достижением в обла-сти онкологии [17]. Стратегии иммунотерапии онкологических заболеваний можно разделить на неспецифические и специфические.…”

Section: Introductionunclassified

Short Overview of Clinical Trials With Current Immunotherapeutic Tools for Cancer Treatment

2017

View full text Add to dashboard Cite

Адрес для переписки:Антонец Денис Викторович ФБУН «Государственный научный центр вирусологии и биотехнологии "Вектор"» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека 630559, Россия, Новосибирская обл., р. п. Кольцово, 28/97. Тел.: 8 (923) 251-81-78. E-mail: antonec@ngs.ru, antonec@yandex.ru Address for correspondence:Antonets Denis V. Vitebsk State Medical University 630559, Russian Federation, Novosibirsk Region, Koltsovo,28, apt 97. Phone: 7 (923) 251-81-78. E-mail: antonec@ngs.ru, antonec@yandex 2017. Т. 19, № 2. С. 127-144. doi: 10.15789/1563-0625-2017-2-127-144 © Непомнящих Т.С. и соавт., 2017 Immunologiya, 2017, Vol. 19, no. 2, pp. 127-144. doi: 10.15789/1563-0625-2017 Резюме. В течение последнего десятилетия был достигнут большой прогресс в понимании био-логии рака и его взаимодействия с иммунной системой. В клинической практике для лечения он-кологических заболеваний широко применяются иммунотерапевтические препараты на основе рекомбинантных цитокинов и моноклональных антител, разработано большое количество экспери-ментальных способов лечения онкологических заболеваний, многие из которых в данный момент проходят различные стадии клинических испытаний. Одобрение рекомбинантного онколитического герпесвируса T-VEC для лечения меланомы стало очередным важным шагом на пути к созданию эф-фективных и безопасных противораковых препаратов. В данном обзоре мы рассмотрим некоторые наиболее перспективные стратегии иммунотерапии онкологических заболеваний: ингибиторы кон-трольных точек иммунного ответа, клеточную терапию и онколитические вирусы. Protection and Human Welfare, Koltsovo, Novosibirsk Region, Russian Federation Abstract. Over last decade, a substantial progress has been made, with respect to understanding of cancer biology and its interplay with the host immune system. Different immunotherapeutic drugs based on recombinant cytokines and monoclonal antibodies are widely used in cancer therapy, and a large number of experimental cancer treatments have been developed, many of which are currently undergoing various stages of clinical trials. Recent endorsement of a recombinant oncolytic herpesvirus T-VEC for the treatment of melanoma was an important step towards a more safe and efficient anticancer therapeutics. In this review, we shall mention only some of the most promising cancer immunotherapy strategies, namely, immune checkpoint inhibitors, cellular therapy and oncolytic viruses. Ключевые слова: рак, иммунотерапия, онколитические вирусы, клинические испытания, вирус осповакцины, Т-лимфоциты, дендритные клетки, химерный антигенный рецептор SHORT OVERVIEW OF CLINICAL TRIALS WITH CURRENT IMMUNOTHERAPEUTIC TOOLS FOR CANCER TREATMENT Nepomnyashchikh T.S., Antonets D.V., Maksyutov R.A. State Research Center of Virology and Biotechnology "Vector", Federal Service for Surveillance on Consumer Rights

show abstract

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Cited by 152 publications

References 66 publications

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Chelerythrine Inhibits Human Hepatocellular Carcinoma Metastasis <i>in Vitro</i>

Short Overview of Clinical Trials With Current Immunotherapeutic Tools for Cancer Treatment

Contact Info

Product

Resources

About